InterMune Inc. ASCENDs to Greatness

InterMune succeeds where Gilead and Novartis failed. Its IPF drug Esbriet looks destined for approval.

Feb 26, 2014 at 9:47AM

Third time is the charm for InterMune (NASDAQ:ITMN). Of course, so was the first.

It was the middle trial that ended up delaying a U.S. approval for its lung drug Esbriet by five years.

Haven't been following biotech for that long? Let's get you caught up.

  • In 2009, the biotech said Esbriet helped patients in both trials, but only one of the two phase 3 trials in a lung disease called idiopathic pulmonary fibrosis demonstrated a statistically significant difference between Esbriet and placebo.
  • An FDA advisory committee voted 9-3 recommending approval of the drug.
  • The FDA ignored its outside advisors and rejected the drug.
  • EU regulators were more forgiving of the mixed data and approved Esbriet.
Esbriet

Source: InterMune.

InterMune went back to the drawing board, designing a new clinical trial, dubbed ASCEND, with more patients than the first two trials to improve the chances of showing statistical significance. The company also measured efficacy at 52 weeks rather than 72 weeks in the previous trials, because the trials showed a treatment effect at 48 weeks, but then the placebo group didn't decline as fast as the Esbriet group so, by 72 weeks, the difference wasn't statistically significant. InterMune also tweaked the primary endpoint; instead of comparing the relative decline in lung capacity -- called percent predicted forced vital capacity, or FVC -- the new trial measured how many patients saw a 10% decline in FVC, which is clinically meaningful.

The changes worked. Big time.

After a year on the drug, 16.5% of patients experienced an FVC decline of 10% or more (patients that died were also included) compared to 31.8% of patients that took placebo. The difference had a p-value of less than 0.000001. Or in other words, there's a 0.0001% chance that the difference happened by chance alone.

Yeah, I'd call that statistically significant.

Ironically, the relative change in FVC was statistically significant as well, so InterMune didn't really have to change the endpoint. Of course, maybe that shouldn't be too surprising since Esbriet did pass one of the two trials with that endpoint.

InterMune plans to submit its new application to the FDA in the third quarter. As far as I can tell, the data looks good enough to get approved by the FDA this time around.

Was the FDA wrong?
Clearly.

In hindsight, at least.

The main argument at the advisory committee meeting seemed to be that there weren't any approved treatments for IPF, so why not just approve it despite the mixed data? As much as investors and companies would like, that's generally not how the FDA works.

While I hate defending the FDA's overly cautious stance, I think the agency was right to be careful with Esbriet considering how hard it's been to treat IPF. In the intervening five years since Esbriet's last trials, a trial for Gilead Sciences' (NASDAQ:GILD) ambrisentan was stopped because of lack of efficacy; Actelion Pharmaceuticals' Tracleer failed to show an effect in IPF, and so did Novartis' (NYSE:NVS) Gleevec. 

There was a report from an unnamed source that Boehringer Ingelheim's nintedanib has passed a phase 3 trial, but the company hasn't confirmed that, as far as I know. Both companies should report data at the American Thoracic Society in May, so we'll know soon enough who might win in the marketplace, assuming they're both approved.

Finding those revolutionary ideas before they're big
Most investors don't understand the key to investing in hyper-growth markets. The trick is to find a small-cap "pure-play," and then watch as it grows in EXPLOSIVE lock-step with it's industry. Our expert team of equity analysts has identified one stock that's poised to produce rocket-ship returns with the next $14.4 TRILLION industry. Click here to get the full story in this eye-opening report.

Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers